Role of intravenous vitamin C on outcomes in hospitalized patients with moderate or severe COVID-19: a real life data of Turkish patients.

Publication date: Nov 13, 2024

We aimed to examine the efficacy of intravenous vitamin C (IV-VC) in the treatment of hospitalized patients with moderate or severe COVID-19. We conducted a single-center and retrospective study including patients with COVID-19 diagnosis who were hospitalized. Patients were categorized into three groups as those who received low-dose (LDVC group, 2 g/day, n = 183) or high-dose IV-VC (HDVC group, 25 g/day, n = 41) and who did not receive IV-VC (control group, n = 46). 270 patients aged 19-97 years were enrolled. The median length of stay (LOS) was significantly high (9 days) in patients treated with high-dose VC when compared to patients treated with low-dose VC and control patients (6 vs 5 days, respectively). Need for intensive care unit (ICU) transfer was found to be significantly low in patients treated with low-dose VC (25. 7%); contrarily, control patients had significantly higher rates of ICU transfer (67. 4%), when compared to patients treated with high-dose VC (39%). Mortality of the LDVC group was significantly lower than that of the HDVC group (11. 5 vs 29. 3%). However, mortality rates were similar between the control and HDVC groups (21. 7 vs 29. 3%). According to the multivariate stepwise logistic regression mortality analysis, percent of change (∆%)-BUN was the most significant variable (p 

Concepts Keywords
5days COVID-19
Inflammopharmacology Intensive care unit
Mortality Intravenous vitamin C
Turkish Length of stay
Vitamin Mortality

Semantics

Type Source Name
disease IDO role
drug DRUGBANK Ascorbic acid
disease MESH COVID-19

Original Article

(Visited 1 times, 1 visits today)